<DOC>
	<DOC>NCT01253603</DOC>
	<brief_summary>This study will assess the safety, efficacy and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma.</brief_summary>
	<brief_title>Efficacy, Safety, and Pharmacokinetics of QAW039</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Patients with a medical history of mild to moderate persistent allergic asthma. Patients must weigh at least 45 kg to participate in the study, and must have abody mass index (BMI) of &gt;17 kg/m2. Female patients must be surgically sterilized, postmenopausal or using a doublebarrier method of contraception Women of childbearing potential. Smokers defined as history of smoking in the previous 6 months or a smoking history of more than 10 pack years, a pack year being defined as smoking the equivalent of 20 cigarettes a pack every day for the period of 1 year Patients with severe persistent asthma Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Asthma</keyword>
</DOC>